612 related articles for article (PubMed ID: 28297679)
1. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
Farshidfar F; Zheng S; Gingras MC; Newton Y; Shih J; Robertson AG; Hinoue T; Hoadley KA; Gibb EA; Roszik J; Covington KR; Wu CC; Shinbrot E; Stransky N; Hegde A; Yang JD; Reznik E; Sadeghi S; Pedamallu CS; Ojesina AI; Hess JM; Auman JT; Rhie SK; Bowlby R; Borad MJ; ; Zhu AX; Stuart JM; Sander C; Akbani R; Cherniack AD; Deshpande V; Mounajjed T; Foo WC; Torbenson MS; Kleiner DE; Laird PW; Wheeler DA; McRee AJ; Bathe OF; Andersen JB; Bardeesy N; Roberts LR; Kwong LN
Cell Rep; 2017 Mar; 18(11):2780-2794. PubMed ID: 28297679
[TBL] [Abstract][Full Text] [Related]
2. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
[TBL] [Abstract][Full Text] [Related]
3. IDH mutations in liver cell plasticity and biliary cancer.
Saha SK; Parachoniak CA; Bardeesy N
Cell Cycle; 2014; 13(20):3176-82. PubMed ID: 25485496
[TBL] [Abstract][Full Text] [Related]
4. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
[TBL] [Abstract][Full Text] [Related]
5. Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.
Goeppert B; Toth R; Singer S; Albrecht T; Lipka DB; Lutsik P; Brocks D; Baehr M; Muecke O; Assenov Y; Gu L; Endris V; Stenzinger A; Mehrabi A; Schirmacher P; Plass C; Weichenhan D; Roessler S
Hepatology; 2019 May; 69(5):2091-2106. PubMed ID: 30615206
[TBL] [Abstract][Full Text] [Related]
6. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
7. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Grassian AR; Pagliarini R; Chiang DY
Curr Opin Gastroenterol; 2014 May; 30(3):295-302. PubMed ID: 24569570
[TBL] [Abstract][Full Text] [Related]
8. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
Saha SK; Parachoniak CA; Ghanta KS; Fitamant J; Ross KN; Najem MS; Gurumurthy S; Akbay EA; Sia D; Cornella H; Miltiadous O; Walesky C; Deshpande V; Zhu AX; Hezel AF; Yen KE; Straley KS; Travins J; Popovici-Muller J; Gliser C; Ferrone CR; Apte U; Llovet JM; Wong KK; Ramaswamy S; Bardeesy N
Nature; 2014 Sep; 513(7516):110-4. PubMed ID: 25043045
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
[TBL] [Abstract][Full Text] [Related]
10. IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
Xiang X; Liu Z; Zhang C; Li Z; Gao J; Zhang C; Cao Q; Cheng J; Liu H; Chen D; Cheng Q; Zhang N; Xue R; Bai F; Zhu J
Adv Sci (Weinh); 2021 Sep; 8(17):e2101230. PubMed ID: 34250753
[TBL] [Abstract][Full Text] [Related]
11. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract][Full Text] [Related]
12. Molecular classification of cholangiocarcinoma.
Louis C; Papoutsoglou P; Coulouarn C
Curr Opin Gastroenterol; 2020 Mar; 36(2):57-62. PubMed ID: 31895230
[TBL] [Abstract][Full Text] [Related]
13. Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.
Wang T; Drill E; Vakiani E; Pak LM; Boerner T; Askan G; Schvartzman JM; Simpson AL; Jarnagin WR; Sigel CS
Hum Pathol; 2019 Sep; 91():19-25. PubMed ID: 31121195
[TBL] [Abstract][Full Text] [Related]
14. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
[TBL] [Abstract][Full Text] [Related]
15. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
Borger DR; Zhu AX
Expert Rev Anticancer Ther; 2012 May; 12(5):543-6. PubMed ID: 22594888
[No Abstract] [Full Text] [Related]
16. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
Jusakul A; Cutcutache I; Yong CH; Lim JQ; Huang MN; Padmanabhan N; Nellore V; Kongpetch S; Ng AWT; Ng LM; Choo SP; Myint SS; Thanan R; Nagarajan S; Lim WK; Ng CCY; Boot A; Liu M; Ong CK; Rajasegaran V; Lie S; Lim AST; Lim TH; Tan J; Loh JL; McPherson JR; Khuntikeo N; Bhudhisawasdi V; Yongvanit P; Wongkham S; Totoki Y; Nakamura H; Arai Y; Yamasaki S; Chow PK; Chung AYF; Ooi LLPJ; Lim KH; Dima S; Duda DG; Popescu I; Broet P; Hsieh SY; Yu MC; Scarpa A; Lai J; Luo DX; Carvalho AL; Vettore AL; Rhee H; Park YN; Alexandrov LB; Gordân R; Rozen SG; Shibata T; Pairojkul C; Teh BT; Tan P
Cancer Discov; 2017 Oct; 7(10):1116-1135. PubMed ID: 28667006
[TBL] [Abstract][Full Text] [Related]
17. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
18. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.
Nepal C; O'Rourke CJ; Oliveira DVNP; Taranta A; Shema S; Gautam P; Calderaro J; Barbour A; Raggi C; Wennerberg K; Wang XW; Lautem A; Roberts LR; Andersen JB
Hepatology; 2018 Sep; 68(3):949-963. PubMed ID: 29278425
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Guilhamon P; Eskandarpour M; Halai D; Wilson GA; Feber A; Teschendorff AE; Gomez V; Hergovich A; Tirabosco R; Fernanda Amary M; Baumhoer D; Jundt G; Ross MT; Flanagan AM; Beck S
Nat Commun; 2013; 4():2166. PubMed ID: 23863747
[TBL] [Abstract][Full Text] [Related]
20. Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features.
Zhu Y; Chen J; Kong W; Mao L; Kong W; Zhou Q; Zhou Z; Zhu B; Wang Z; He J; Qiu Y
Eur Radiol; 2018 Jan; 28(1):159-169. PubMed ID: 28752218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
